Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Alabama at Birmingham Medical Center, Birmingham, Alabama